VoxCell BioInnovation and adMare BioInnovations have announced a research partnership to advance novel antibody therapies in non-animal models. VoxCell says its human-relevant vascularised tissue platform brings together human tumour, immune, and stromal compartments alongside a perfused, endothelial-lined vasculature in a single bioprinted construct. The result is a… Read More
The Association of the British Pharmaceutical Industry (ABPI) has urged scientists to develop better pre-clinical models to accelerate the development of new medicines. The ABPI, in collaboration with the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), has published a landmark review examining the… Read More
Mariana Argenziano, Associate Director Manufacturing Technologies, and Jeroen de Groot, Divisional Chief Executive Officer at Ncardia, explore how human-relevant preclinical research can move the industry past its reliance on animal models. In April 2025, the US Food and Drug Administration (FDA) released a roadmap to reducing animal… Read More
Biotech company Parallel Bio has raised $21 million in a Series A funding led by AIX Ventures. The round attracted new investors Amplo and Marc Benioff, founder and CEO of Salesforce, and existing investors Metaplanet, Humba Ventures, Atypical Ventures, Undeterred Capital, and Jeff Dean. Robert… Read More
Dr Isaac Bentwich, Founder and CEO of Quris-AI examines the rise of alternative approaches to animal testing within drug discovery. Since the Federal Food, Drug, and Cosmetic Act of 1938, animal testing has served as the foundational model for biomedical research, offering scientists insights into disease mechanisms and drug safety. Read More
Scientists at the Cancer Research Manchester Institute have created a new model of Lung Squamous Cell Carcinoma (LUSC) to study the development, activity, and vulnerabilities of the disease. In the UK, around 80 to 85% of lung cancers are non-small cell lung cancer, of which squamous cell… Read More
A decade ago, researchers introduced a new model for studying Alzheimer’s disease (AD). Known as ‘Alzheimer’s in a dish’, the model uses cultures of mature brain cells suspended in a gel to recapitulate what takes place in the human brain over 10 to 13 years in just six weeks. Read More
Organ-Chips have seen significant growth in adoption over the past few years. A blinded survey across industry and academia found: 97% of experienced Organ-Chip users say the technology is more predictive than conventional in vitro models. 70% of experienced Organ-Chip users describe the technology as more predictive than… Read More
Organ-Chips have seen significant growth in adoption over the past few years. A blinded survey across industry and academia found: 97% of experienced Organ-Chip users say the technology is more predictive than conventional in vitro models. 70% of experienced Organ-Chip users describe the technology as more predictive than… Read More
Professor Andy Whiting, CEO of Nevrargenics, asks whether animal models should be used as the default regulatory requirement and explores the times to use them. Animal models (AMs) have generally been seen as useful for drug development and biomedical research for many years. They are assumed to closely mimic human… Read More
Scientists have created the first bioengineered bone marrow model which can support the type of human stem cells that are crucial for bone marrow transplants and in vitro study work. The research – published in Nature Communications and led by the University of… Read More
New survey findings have revealed that 77% of R&D professionals are not using in vitro cell-based alternatives to animal testing, and only 23% describe themselves as ‘very familiar’ with any kind of animal model alternative. More than 350 survey respondents participated in the survey by The… Read More
